Mogrify Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 25

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $10.2M

  • Investors
  • 13

Mogrify General Information

Description

Developer of a cellular technology designed to enhance patient care through the development of a novel class of in vivo reprogramming therapies. The company's technology addresses indications in the fields of ophthalmology, otology, and metabolic and other degenerative diseases, uses its proprietary platform technology to direct cell reprogramming and systematically generate functional cell types for disease treatment, enabling researchers to address the issues of efficacy, safety, and scalability which are associated with cell therapy development and manufacturing.

Contact Information

Formerly Known As
Cell Mogrify
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 25 Cambridge Science Park
  • Milton Road, Milton
  • Cambridge CB4 0FW
  • England, United Kingdom
+44 01223
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 25 Cambridge Science Park
  • Milton Road, Milton
  • Cambridge CB4 0FW
  • England, United Kingdom
+44 01223

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mogrify Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series A) 05-Sep-2023 $10.2M Completed Startup
7. Later Stage VC (Series A) 04-May-2021 Completed Startup
6. Grant 28-Jan-2020 Completed Startup
5. Early Stage VC (Series A) 14-Oct-2019 Completed Startup
4. Grant 18-Mar-2019 Completed Startup
3. Seed Round 20-Feb-2019 Completed Startup
2. Seed Round 16-Dec-2016 $376K $376K Completed Startup
1. University Spin-Out 12-Feb-2016 Completed Startup
To view Mogrify’s complete valuation and funding history, request access »

Mogrify Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
C Ordinary
C Ordinary
C Ordinary
C Ordinary
C Ordinary
B Ordinary
B Ordinary
B Ordinary
B Ordinary 1,700 $0.000013 $19.02 $19.02 $19.02 0.12%
B Ordinary 42,000 $0.000013 $3.62 $3.62 $3.62 3.06%
To view Mogrify’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Mogrify Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a cellular technology designed to enhance patient care through the development of a novel class of in vivo
Discovery Tools (Healthcare)
Cambridge, United Kingdom
25 As of 2025

New York, NY
 

Lund, Sweden
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mogrify Competitors (24)

One of Mogrify’s 24 competitors is Brainstorm Cell Therapeutics, a Corporation company based in New York, NY.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Brainstorm Cell Therapeutics Corporation New York, NY
Asgard Therapeutics Venture Capital-Backed Lund, Sweden
Sirnaomics Formerly VC-backed Gaithersburg, MD
Orgenesis Corporation Germantown, MD
Neurogene Formerly VC-backed New York, NY
You’re viewing 5 of 24 competitors. Get the full list »

Mogrify Patents

Mogrify Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202415089-D0 Cell conversion Pending 14-Oct-2024
WO-2026083068-A1 Cell conversion Pending 14-Oct-2024
GB-202407725-D0 Cell conversion Inactive 31-May-2024
WO-2025248252-A1 Cell conversion into cochlear hair cells Pending 31-May-2024
EP-4508223-A1 Cell conversion Pending 11-Apr-2022 C07K14/4705
To view Mogrify’s complete patent history, request access »

Mogrify Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mogrify Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Angel (individual) Minority
Meltwind Advisory Venture Capital Minority
Astellas Venture Management Corporate Venture Capital Minority
Trend Investment Group Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Mogrify Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Chondrogenix Cambridge, United Kingdom 2017

Mogrify FAQs

  • When was Mogrify founded?

    Mogrify was founded in 2016.

  • Where is Mogrify headquartered?

    Mogrify is headquartered in Cambridge, United Kingdom.

  • What is the size of Mogrify?

    Mogrify has 25 total employees.

  • What industry is Mogrify in?

    Mogrify’s primary industry is Discovery Tools (Healthcare).

  • Is Mogrify a private or public company?

    Mogrify is a Private company.

  • What is the current valuation of Mogrify?

    The current valuation of Mogrify is .

  • What is Mogrify’s current revenue?

    The current revenue for Mogrify is .

  • How much funding has Mogrify raised over time?

    Mogrify has raised $49.9M.

  • Who are Mogrify’s investors?

    , , Meltwind Advisory, Astellas Venture Management, and Trend Investment Group are 5 of 13 investors who have invested in Mogrify.

  • Who are Mogrify’s competitors?

    Brainstorm Cell Therapeutics, Asgard Therapeutics, Sirnaomics, Orgenesis, and Neurogene are some of the 24 competitors of Mogrify.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process